Trial Profile
A Phase II Trial of Bortezomib, Doxorubicin and Dexamethasone (PAD) Induction Therapy in Patients With Untreated Multiple Myeloma (MM), Stratified for Markers of Bortezomib Resistance.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone; Doxorubicin
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms PIMMS
- Sponsors Janssen-Cilag
- 16 May 2012 Actual patient number changed from 108 to 107 as reported by ClinicalTrials.gov.
- 16 May 2012 Actual end date (1 Nov 2011) added as reported by ClinicalTrials.gov.
- 16 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.